骨质疏松症
医学
骨吸收
双膦酸盐
骨重建
骨矿物
不利影响
骨病
内科学
骨密度保护剂
生物信息学
生物
作者
Ahmad Oryan,Sonia Sahvieh
出处
期刊:Life Sciences
[Elsevier]
日期:2021-01-01
卷期号:264: 118681-118681
被引量:32
标识
DOI:10.1016/j.lfs.2020.118681
摘要
Osteoporosis is a bone disease that mainly affects older people and postmenopausal women. Lack of proper treatment for this disease gives rise to many problems in patients and occasionally leads to death. Many drugs have been utilized to treat osteoporosis but the most effective one is the bisphosphonates (BPs) family. This family has several positive effects on bone tissue, including promoting bone healing, enhancing bone mineral density, reducing bone resorption, preventing pathologic fractures, suppressing bone turnover, and modulating bone remodeling. On the other hand, there have also been inconclusive reports that BPs might have a desirable or even adverse impact on osteoporotic patients. Therefore, we set out to examine the positive and negative effects of this family, with a focus on the most potent one that is zoledronate (Zol), in clinical usage. Zoledronate is an amino-BPs and nitrogen-containing drug which is the most powerful BPs on osteoporosis treatment or prevention. Many studies showed its effectiveness in the treatment of osteoporosis and bone healing. As Zol enjoys a considerable potential in treating and preventing osteoporosis, it can be used as one of the effective treatments in this field.
科研通智能强力驱动
Strongly Powered by AbleSci AI